We report 2 cases of late recurrence of osteosarcoma after 6 and 7 years. One patient had pulmonary metastasis, and the other had soft tissue recurrence. Both patients underwent complete resection and chemotherapy. The first patient achieved complete remission and remained disease-free 47 months later and had no limitation in his daily life. The second patient had a re-recurrence and underwent further resection and chemotherapy. He remained disease-free 35 months later and could walk using a T-handled walking cane.
StillerCABielackSSJundtGSteliarova-FoucherE. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer2006;42:2124–35.
2.
StillerCACraftAWCorazziariI, EUROCARE Working Group. Survival of children with bone sarcoma in Europe since 1978: Results from the EUROCARE study. Eur J Cancer2001;37:760–6.
3.
LinkMPGoorinAMMiserAWGreenAAPrattCBBelascoJB. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med1986;314:1600–6.
4.
EilberFGiulianoAEckardtJPattersonKMoseleySGoodnightJ. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol1987;5:21–6.
5.
SouhamiRLCraftAWVan der EijkenJWNooijMSpoonerDBramwellVH. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet1997;350:911–7.
6.
FuchsNBielackSSEplerDBielingPDellingGKörholzD. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol1998;9:893–9.
7.
FerrariSBacciGPicciPMercuriMBriccoliAPintoD. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol1997;8:765–71.
8.
BacciGFerrariSBertoniFRuggieriPPicciPLonghiA. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/ osteosarcoma-2 protocol: An updated report. J Clin Oncol2000;18:4016–27.
9.
MeyersPAHellerGHealeyJHuvosALaneJMarcoveR. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol1992;10:5–15.
10.
FerrariSBertoniFMercuriMPicciPGiacominiSLonghiA. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol2001;12:1145–50.
11.
BielackSSKempf-BielackBDellingGExnerGUFlegeSHelmkeK. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol2002;20:776–90.
12.
StraussSJMcTiernanAWhelanJS. Late relapse of osteosarcoma: Implications for follow-up and screening. Pediatr Blood Cancer2004;43:692–7.
13.
Kempf-BielackBBielackSSJurgensHBranscheidDBerdelWEExnerGU. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol2005;23:559–68.
14.
LauCCPardeeAB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci U S A1982;79:2942–6.
15.
TomitaKTsuchiyaH. Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma. Clin Ther1989;11:43–52.
16.
TsuchiyaHYamamotoNAsadaNTerasakiTKanazawaYTakanakaT. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res2000;20:2137–43.
17.
FerrariSBriccoliAMercuriMBertoniFCesariMLonghiA. Late relapse in osteosarcoma. J Pediatr Hematol Oncol2006;28:418–22.
18.
SaeterGKlokeOJelicS; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of osteosarcoma. Ann Oncol2005;16(Suppl 1):i71–2.
19.
MerimskyOMellerIKollenderYInbarM. Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer1998;34:1296–7.
20.
HuangPChubbSHertzelLWGrindeyGBPlunkettW. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res1991;51:6110–7.
21.
OkunoSEdmonsonJMahoneyMBucknerJCFrytakSGalanisE. Phase II trial of gemcitabine in advanced sarcomas. Cancer2002;94:3225–9.
22.
SvancarovaLBlayJYJudsonIRvan HoeselQGvan OosteromATle CesneA. Gemcitabine in advanced adult soft tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2002;38:556–9.
23.
MerimskyOMellerIFlusserGKollenderYIssakovJWeil-Ben-ArushM. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol2000;45:177–81.
24.
Späth-SchwalbeEGenvresseIKoschuthADietzmannAGrunewaldRPossingerK. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs2000;11:325–9.
25.
PatelSRGandhiVJenkinsJPapadopolousNBurgessMAPlagerC. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol2001;19:3483–9.
26.
NishidaHTsuchiyaHTomitaK. Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br2008;90:1249–55.
27.
NishidaHYamamotoNTanzawaYTsuchiyaH. Cryoimmunology for malignant bone and soft-tissue tumors. Int J Clin Oncol2011;16:109–17.
